Format

Send to

Choose Destination
Oncotarget. 2017 Mar 21;8(12):19556-19565. doi: 10.18632/oncotarget.14700.

Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.

Author information

1
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China.
2
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
3
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China.

Abstract

We retrospectively analyzed LMR at diagnosis and at completion of first-line therapy and prognosis in173 patients with DLBCL from 2005 to 2016. We found that patients with an LMR < 3.2 at diagnosis, as well as at completion of first-line therapy, had significantly lower PFS and OS rates than those with an LMR ≥ 3.2 (P<0.05). Patients with LMR that recovered from the low level at diagnosis showed superior overall survival (OS) (P=0.000) and progression-free survival (PFS) (P=0.001) compared with patients who failed to achieve a higher value at the completion of therapy. The multivariate analysis demonstrated that LMR values that did not increase upon completion of first-line therapy were an independent predictor for inferior OS (P=0.021) and PFS (P=0.046). In conclusion, LMR at diagnosis and at completion of first-line therapy is a simple biomarker to predict clinical outcomes in DLBCL. LMR recovery from low levels at diagnosis, irrespective of whether LMR reached the cutoff value, was associated with improved clinical outcomes.

KEYWORDS:

diffuse large B-cell lymphoma; lymphocyte; monocyte; prognosis

PMID:
28107187
PMCID:
PMC5386705
DOI:
10.18632/oncotarget.14700
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center